Other

Chiba Flour Milling Co., Ltd.

Kose Corporation

Daisuke Tsukioka

Gen-Ichiro Soma

Haruyuki Oshima

Den'ichi Mizuno

Kiyoshi Yoshimura

Takanao Suzuki

Jun Yoshimura

Hiroyuki Ohno

Natsue Kawahara

Satsuki Miyagawa

Hideaki Koike

Yuriko Tomita

Keiji Igarashi

Den'Ichi Mizuno

An object of the present invention is to provide novel dextrin fatty acid ester that is excellent in tackiness and useful as a base for cosmetics and the like. The novel dextrin fatty acid ester is prepared by esterification between dextrin and fatty acids, wherein the dextrin has an average degree of glucose polymerization of 3 to 150; the fatty acids comprise more than 50 mol % and 100 mol % or less, based on the total amount of the fatty acids, of one or more saturated branched fatty acids having 4 to 26 carbon atoms, and 0 mol % or more and less than 50 mol %, based on the total amount of the fatty acids, of one or more fatty acids selected from the group consisting of saturated linear fatty acids having 2 to 22 carbon atoms, unsaturated linear or branched fatty acids having 6 to 30 carbon atoms, and saturated or unsaturated cyclic fatty acids having 6 to 30 carbon atoms; and the degree of substitution by the fatty acids is 1.0 to 3.0 per glucose unit.

Dextrin fatty acid ester that does not cause gelation of liquid oil, and uses thereof

A modified organopolysiloxane in which a carboxyl group of a heterocyclic compound having a carboxyl group and containing a nitrogen atom as a heteroatom is combined with an amino group of an amino-modified silicone is used as a gelling agent for low-viscosity silicone oil, which can allow the low-viscosity silicone oil to stably gel without losing the characteristics thereof.

Modified organopolysiloxanes, production thereof and compositions

A pure culture of Pantoea agglomerans having all of the characteristics of FERM BP-3511 is disclosed. The characteristics include morphology, growth, physiological, carbon utilization sources and various enzymatic tests, as well as the required production of a lipopolysaccharide and all of these characteristics have been identified for the culture of P. agglomerans. In addition the lipopolysaccharide has a dominant molecular weight of 6,500.+-.2,500 as determined by SDS-PAGE method, 2.+-.phosphorus, 5.+-.hexosamines and 2.+-.1 2-keto-3-deoxyoctonate per molecular weight of 5,000. The specific enzymatic tests involve such enzymes as lysin decarboxylase, arginine dihydroxylase, phenylalanine deaminase and ornithine decarboxylase. Further, a test for utilization of malonate by the culture is disclosed.

Pure culture of Pantoea agglomerans ferm BP-3511

Antiwithdrawal agents and veterinary antiwithdrawal agents are disclosed which contain lipopolysaccharide (LPS) representatives which have the following physical properties:

Method for the treatment of narcotic withdrawal symptoms in animals

A limulus test-positive plant glycolipid having the following properties: molecular weight: 8000 .+-.1000 by SDS electrophoresis, number of phosphorous not less than 1/mol; number of hexosamine 6 .+-.2/mol; number of fatty acids 6 .+-.2/mol is effective in the stimulation of osteogenesis, oviposition and shell strength improvement in animals. The glycolipid may be administered as a composition comprising an effective amount of the glycolipid in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, the immune system of the animal is favorably stimulated.

Method for the stimulation of the immune system of an animal by use of

Novel LPS having the following physical properties, novel bacilli providing those LPS, and novel immunity stimulators, anagesics, and antiwithdrawal agents, and novel veterinary immunity stimulators, analgesics, and antiwithdrawal agents containing LPS selected from the group consisting of those LPSs and mixtures thereof. LPS1 Dominant molecular weight: 5,000.+-.1,000 as determined by

Lipopolysaccharide-producing bacteria, lipopolysaccharides, and

An analgesic composition comprising an effective amount of at least one member of LPS whose macrophage activation ED.sub.50 is 0.4-100 ng/ml of culture solution in terms of its limulus test-positive LPS content observed on a sigmoid curve prepared by determining the ability of the LPS to activate the TNF productivity of macrophage cultured in vitro, and plotting the macrophage activation ability (%) along the axis of ordinate wherein the ability is estimated to be 0% in the case where it corresponds to the quantity of TNF produced by macrophage with no LPS added thereto, and 100% is assigned to the macrophage activation ability which provides the maximal and constant quantity of TNF produced by the macrophage and plotting the limulus test-positive LPS content of the LPS along the axis of abscissa on a logarithmic scale, in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, high cholesterol level of said animal is prevented or cured; and a method of treating pain of an animal comprising administration to said animal an amount of the above composition effective to prevent or cure the pain of said animal.

LPS-containing analgesics and veterinary analgesics

A limulus test-positive plant glycolipid having the following properties:

Growing community of inventors

Chiba, Japan

Daisuke Tsukioka